BioWorld MedTech

Sep. 23, 2016

View Archived Issues

Canon makes bet on molecular diagnostics with $40M investment in T2 Biosystems

The stock of molecular diagnostics company T2 Biosystems Inc. spiked 10 percent due to a $40 million equity investment from Melville, N.Y.-based Canon U.S.A. Inc., made in return for a nearly 20 percent stake in the firm. Read More

Shuren says MDUFA IV would add $6 million a year for NEST program

Read More

Observational study predicts reassessment of French coronary stent reimbursement program

Read More

Claret Medical files for FDA clearance of its Sentinel cerberal protection system

Read More

Regulatory Front

Read More

Daily M&A

Read More

Appointments and advancements

Read More

Product briefs

Read More

Financings

Read More

MDD's Diagnostics Extra

Read More